Patents by Inventor Thomas Harding

Thomas Harding has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Afucosylated Anti-FGFR2IIIB Antibodies
    Publication number: 20220168416
    Abstract: The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated. The present invention provides compositions comprising antibodies that bind FGFR2IIIb, wherein at least 95% of the antibodies in the composition are afucosylated. In some embodiments, methods of treating cancer comprising administering afucosylated anti-FGFR2IIIb antibodies are provided.
    Type: Application
    Filed: December 17, 2021
    Publication date: June 2, 2022
    Applicant: Five Prime Therapeutics, Inc.
    Inventors: Thomas Harding, Kristen Pierce, Namrata Patil, Thomas Brennan, Julie Hambleton
  • Afucosylated anti-FGFR2IIIB antibodies
    Patent number: 11235059
    Abstract: The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated. The present invention provides compositions comprising antibodies that bind FGFR2IIIb, wherein at least 95% of the antibodies in the composition are afucosylated. In some embodiments, methods of treating cancer comprising administering afucosylated anti-FGFR2IIIb antibodies are provided.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: February 1, 2022
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Thomas Harding, Kristen Pierce, Namrata Patil, Thomas Brennan, Julie Hambleton
  • Method for recovering hydrocarbons from low permeability formations
    Patent number: 10760391
    Abstract: There is provided a method of producing hydrocarbon material. A first hydrocarbon material is produced from the formation, the first hydrocarbon material including a gaseous hydrocarbon material originally in place in the formation. At least a portion of the produced gaseous hydrocarbon material is injected into the formation to increase the formation pressure. A second hydrocarbon material is produced from the formation.
    Type: Grant
    Filed: November 16, 2016
    Date of Patent: September 1, 2020
    Assignee: CNOOC PETROLEUM NORTH AMERICA ULC
    Inventors: Roberto Aguilera, Alfonso Fragoso, Yi Wang, Guicheng Jing, Karthikeyan Selvan, Thomas Harding, Faisal Qureshi
  • Methods of treating lung cancer
    Patent number: 10537611
    Abstract: Methods of treating cancers comprising FGFR1 gene amplification are provided. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: January 21, 2020
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Thomas Harding, Servando Palencia, Li Long, Kevin Hestir
  • Processes for producing hydrocarbons from a reservoir
    Patent number: 10344579
    Abstract: There is provided a process for producing hydrocarbons from a reservoir. The process includes within the hydrocarbon reservoir, electrically heating a liquid heating fluid such that the liquid heating fluid is evaporated to produce a gaseous heating fluid, heating hydrocarbon material with the gaseous heating fluid such that the heated hydrocarbon material is mobilized and such that the gaseous heating fluid is condensed to produce a condensed heating fluid, and electrically heating at least a fraction of the condensed heating fluid such that the at least a condensed heating fluid fraction is re-evaporated, and while the evaporation, the condensing, and the re-evaporation are being effected, producing a produced fluid including at least the mobilized hydrocarbon material.
    Type: Grant
    Filed: May 7, 2015
    Date of Patent: July 9, 2019
    Assignee: CNOOC PETROLEUM NORTH AMERICA ULC
    Inventors: Thomas Harding, Richard Kelso Kerr, Ann Chen Howe
  • Afucosylated Anti-FGFR2IIIB Antibodies
    Publication number: 20190175730
    Abstract: The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated. The present invention provides compositions comprising antibodies that bind FGFR2IIIb, wherein at least 95% of the antibodies in the composition are afucosylated. In some embodiments, methods of treating cancer comprising administering afucosylated anti-FGFR2IIIb antibodies are provided.
    Type: Application
    Filed: November 6, 2018
    Publication date: June 13, 2019
    Applicant: Five Prime Therapeutics, Inc.
    Inventors: Thomas Harding, Kristen Pierce, Namrata Patil, Thomas Brennan, Julie Hambleton
  • Method of treatment of malignant solid tumors with afucosylated anti-FGFR2IIIb antibodies
    Patent number: 10172937
    Abstract: The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated. The present invention provides compositions comprising antibodies that bind FGFR2IIIb, wherein at least 95% of the antibodies in the composition are afucosylated. In some embodiments, methods of treating cancer comprising administering afucosylated anti-FGFR2IIIb antibodies are provided.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: January 8, 2019
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Thomas Harding, Kristen Pierce, Namrata Patil, Thomas Brennan, Julie Hambleton
  • Methods of Treating Cancer
    Publication number: 20190000920
    Abstract: Methods of treating cancers comprising FGFR1 gene amplification are provided. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent.
    Type: Application
    Filed: June 8, 2018
    Publication date: January 3, 2019
    Applicant: Five Prime Therapeutics, Inc.
    Inventors: Thomas Harding, Servando Palencia, Li Long, Kevin Hestir
  • Processes for producing hydrocarbons from a reservoir
    Patent number: 10041341
    Abstract: There is provided a process for producing hydrocarbons from a reservoir. The process includes within the hydrocarbon reservoir, electrically heating a liquid heating fluid such that the liquid heating fluid is evaporated to produce a gaseous heating fluid, heating hydrocarbon-comprising material with the gaseous heating fluid such that the heated hydrocarbon-comprising material is mobilized and such that the gaseous heating fluid is condensed to produce a condensed heating fluid, and electrically heating at least a fraction of the condensed heating fluid such that the at least a condensed heating fluid fraction is re-evaporated, and while the evaporation, the condensing, and the re-evaporation are being effected, producing a produced fluid including at least the mobilized hydrocarbon-comprising material.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: August 7, 2018
    Assignee: NEXEN ENERGY ULC
    Inventors: Richard Kelso Kerr, Thomas Harding
  • Methods of treating lung cancer
    Patent number: 10016484
    Abstract: Methods of treating cancers comprising FGFR1 gene amplification are provided. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent.
    Type: Grant
    Filed: November 13, 2012
    Date of Patent: July 10, 2018
    Assignee: FIVE PRIME THERAPEUTICS, INC.
    Inventors: Thomas Harding, Servando Palencia, Li Long, Kevin Hestir
  • Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer
    Patent number: 9669081
    Abstract: The present invention relates to prostate cancer markers, compositions comprising such markers, and methods of using such markers to induce or increase an immune response against prostate cancer. An immune response against the markers correlates with an immune response, in particular a humoral immune response, against prostate cancer cells which immune response is preferably associated with prophylaxis of prostate cancer, treatment of prostate cancer, and/or amelioration of at least one symptom associated with prostate cancer.
    Type: Grant
    Filed: September 19, 2014
    Date of Patent: June 6, 2017
    Assignee: ADURO GVAX, INC.
    Inventors: Karin Jooss, Thomas Harding, Minh Nguyen, Kathryn E. Koprivnikar
  • AFUCOSYLATED ANTI-FGFR2IIIB ANTIBODIES
    Publication number: 20160339100
    Abstract: The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated. The present invention provides compositions comprising antibodies that bind FGFR2IIIb, wherein at least 95% of the antibodies in the composition are afucosylated. In some embodiments, methods of treating cancer comprising administering afucosylated anti-FGFR2IIIb antibodies are provided.
    Type: Application
    Filed: May 27, 2016
    Publication date: November 24, 2016
    Applicant: Five Prime Therapeutics, Inc.
    Inventors: Thomas Harding, Kristen Pierce, Namrata Patil, Thomas Brennan, Julie Hambleton
  • FAM150A, FAM150B, AND FAM150 ANTAGONISTS AND USES THEREOF
    Publication number: 20160017024
    Abstract: Methods of identifying and using FAM150A agents, FAM150B agents, and FAM150 antagonists are provided. Methods of identifying and using LTK agonists (including LTK agonist antibodies, FAM150A agents, and FAM150B agents) and FAM150 antagonists are provided. Such methods include, but are not limited to, methods of treating cancer, methods of treating immune disorders such as autoimmune diseases, and methods of treating neurodegenerative diseases.
    Type: Application
    Filed: March 7, 2014
    Publication date: January 21, 2016
    Inventors: Lewis T. Williams, Hongbing Zhang, Kevin Hester, Thomas Harding
  • Method of treatment of cancers characterized by ligand-dependent activating mutations in FGFR2 with FGFR1 ECD proteins
    Patent number: 9169313
    Abstract: The present invention relates to the use of Fibroblast Growth Factor Receptor I (FGFR1) extracellular domain (ECD) polypeptides for treatment of cancers characterized by ligand dependent activating mutations in Fibroblast Growth Factor Receptor 2 (FGFR2). For example, the present invention relates to the treatment of endometrial cancers and other cancers wherein tumor cells express FGFR2 mutants in the IgII-IgIII hinge region or IgIII domain of the protein, such as at amino acid positions 252 and/or 253.
    Type: Grant
    Filed: November 14, 2013
    Date of Patent: October 27, 2015
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Thomas Harding, W. Michael Kavanaugh
  • AFUCOSYLATED ANTI-FGFR2IIIB ANTIBODIES
    Publication number: 20150050273
    Abstract: The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated. The present invention provides compositions comprising antibodies that bind FGFR2IIIb, wherein at least 95% of the antibodies in the composition are afucosylated. In some embodiments, methods of treating cancer comprising administering afucosylated anti-FGFR2IIIb antibodies are provided.
    Type: Application
    Filed: July 31, 2014
    Publication date: February 19, 2015
    Inventors: Thomas Harding, Kristen Pierce, Namrata Patil, Thomas Brennan, Julie Hambleton
  • METHODS OF TREATING CANCER
    Publication number: 20140341900
    Abstract: Methods of treating cancers comprising FGFR1 gene amplification are provided. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent.
    Type: Application
    Filed: November 13, 2012
    Publication date: November 20, 2014
    Inventors: Thomas Harding, Servando Palencia, Li Long, Kevin Hestir
  • Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer
    Patent number: 8840881
    Abstract: The present invention relates to prostate cancer markers, compositions comprising such markers, and methods of using such markers to induce or increase an immune response against prostate cancer. An immune response against the markers correlates with an immune response, in particular a humoral immune response, against prostate cancer cells which immune response is preferably associated with prophylaxis of prostate cancer, treatment of prostate cancer, and/or amelioration of at least one symptom associated with prostate cancer.
    Type: Grant
    Filed: August 24, 2009
    Date of Patent: September 23, 2014
    Assignee: Aduro Gvax Inc.
    Inventors: Karin Jooss, Thomas Harding, Minh Nguyen, Kathryn E. Koprivnikar
  • USE OF FGFR1 EXTRA CELLULAR DOMAIN PROTEINS TO TREAT CANCERS CHARACTERIZED BY LIGAND-DEPENDENT ACTIVATING MUTATIONS IN FGFR2
    Publication number: 20140227263
    Abstract: The present invention relates to the use of Fibroblast Growth Factor Receptor I (FGFR1) extracellular domain (ECD) polypeptides for treatment of cancers characterized by ligand dependent activating mutations in Fibroblast Growth Factor Receptor 2 (FGFR2). For example, the present invention relates to the treatment of endometrial cancers and other cancers wherein tumor cells express FGFR2 mutants in the IgII-IgIII hinge region or IgIII domain of the protein, such as at amino acid positions 252 and/or 253.
    Type: Application
    Filed: November 14, 2013
    Publication date: August 14, 2014
    Applicant: FIVE PRIME PHARMACEUTICALS, INC.
    Inventors: Thomas Harding, W. Michael Kavanaugh
  • Use of FGFR1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in FGFR2
    Patent number: 8614183
    Abstract: The present invention relates to the use of Fibroblast Growth Factor Receptor I (FGFR1) extracellular domain (ECD) polypeptides for treatment of cancers characterized by ligand dependent activating mutations in Fibroblast Growth Factor Receptor 2 (FGFR2). For example, the present invention relates to the treatment of endometrial cancers and other cancers wherein tumor cells express FGFR2 mutants in the IgII-IgIII hinge region or IgIII domain of the protein, such as at amino acid positions 252 and/or 253.
    Type: Grant
    Filed: November 12, 2010
    Date of Patent: December 24, 2013
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Thomas Harding, W. Michael Kavanaugh
  • METHODS OF TREATING CANCER
    Publication number: 20130136740
    Abstract: Methods of treating cancers comprising FGFR1 gene amplification are provided. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent.
    Type: Application
    Filed: November 13, 2012
    Publication date: May 30, 2013
    Inventors: Thomas Harding, Servando Palencia, Li Long, Kevin Hestir